Despite mixed results, Roche nabs FDA win for Actemra To view this email as a web page,
click here | | Webinar: New Trends in Virtual Trials Monday, July 26 | 11am ET / 8am PT Last year, clinical trial platform developer Medable raised $91M in private funding, amid the COVID-19 pandemic that touched off huge demand among pharma companies looking to initiate “siteless” or virtual clinical trials. Explore the role of CROs in siteless trials and the opportunities and challenges for CROs to expand their capabilities in this burgeoning area. Register now. |
Lilly's COVID antibody combo halted nationwide, dealing huge blow to blockbuster program Roche nabs FDA emergency nod for Actemra in severe COVID-19 despite mixed trial results COVID-19 tracker: World is 'failing' as poor nations go without shots, WHO chief says; Lilly antibody halted in US Biden quietly transforms Medicaid safety net Featured Story | By Fraiser Kansteiner,Eric Sagonowsky With a pair of troubling coronavirus variants on the rise, the U.S. is pausing national distribution of Eli Lilly’s COVID-19 antibody combo of bamlanivimab and etesevimab until further notice. read more |
| |
|---|
|
Top Stories By Angus Liu Roche’s Actemra may have turned up mixed results in COVID-19 clinical trials, but the FDA thinks the rheumatoid arthritis drug has shown enough benefit in some severe patients to deserve an emergency use authorization. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The head of the World Health Organization scolded richer nations for vaccinating their entire populations, even those less at-risk, before sending doses to poorer countries. Shipments of Eli Lilly's antibody combo were halted in the U.S. because of variant concerns. And more headlines. read more By Noam N. Levey, Kaiser Health News,Phil Galewitz, Kaiser Health News The Biden administration is quietly engineering a series of expansions to Medicaid that may bolster protections for millions of low-income Americans and bring more people into the program. read more | | Webinar: COVID-19 Virus Sequencing for Drug Development Wednesday, July 28 | 10:30am ET / 7:30am PT As new COVID-19 variants continue to emerge, virus sequencing will play critical and ongoing role in drug and vaccine development. This webinar will connect insights from population surveillance to potential solutions for drug developers, outline approaches to COVID-19 virus sequencing and more. Register Now. |
|
|
